Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Pictilisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 16/20 | 0.95 |
| ▸ | PIK3CD known ✓ | O00329 | 14/20 | 0.95 |
| ▸ | PIK3CB known ✓ | P42338 | 13/20 | 0.95 |
| ▸ | PIK3CG known ✓ | P48736 | 11/20 | 0.95 |
| ▸ | PIK3R2 known ✓ | O00459 | 1/20 | 0.95 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.95 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 1/20 | 0.95 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.95 |
| ▸ | PLK4 | O00444 | 1/20 | 0.95 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.95 |
| ▸ | GAK | O14976 | 1/20 | 0.95 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.95 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.95 |
| ▸ | STK16 | O75716 | 1/20 | 0.95 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.95 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.95 |
| ▸ | NQO2 | P16083 | 1/20 | 0.95 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pictilisib SCHEMBL29915227 | 1.00 | ABCC4 (1.00) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| Pictilisib SCHEMBL29375636 | 0.98 | PIK3CA (1.00) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| Pictilisib SCHEMBL190812 | 0.98 | PIK3CA (1.00) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| Pictilisib SCHEMBL29387739 | 0.98 | PIK3CA (1.00) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| Pictilisib SCHEMBL14859338 | 0.98 | PIK3CA (1.00) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| Pictilisib SCHEMBL3045698 | 0.96 | ABCC4 (0.92) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| SCHEMBL190513 | 0.95 | PIK3CA (0.95) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| Pictilisib SCHEMBL31237882 | 0.94 | PIK3CA (0.89) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| SCHEMBL31205 | 0.92 | PIK3CA (0.88) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB | |
| SCHEMBL190211 | 0.91 | PIK3CA (0.87) | ABCC4ABCB11PIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4234546-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12583854-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12582657-B2 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4048671-B1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | AMGEN INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12540129-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4685160-A2 | COMBINATION THERAPY INCLUDING A KRASG12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | Amgen Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4684786-A2 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260007665-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | AMGEN INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-11306087-B2 | Inhibitors of KRAS G12C and methods of using the same | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220106293-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3974429-A1 | PRECURSORS OF KRAS G12C INHIBITORS | Amgen Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3968998-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | Amgen, Inc (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220056015-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | PIK3CA 48/4885PIK3CD 151/4885PIK3CB 208/4885 |
| US-20220073504-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | PIK3CA 222/4885PIK3CD 232/4885PIK3CB 170/4885 |
| US-20220106293-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | PIK3CA 244/4885PIK3CD 253/4885PIK3CB 182/4885 |
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | KRAS, NRAS, HRAS | PIK3CA 45/4885PIK3CD 175/4885PIK3CB 179/4885 |
| US-12637445-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF2C | PIK3CA 791/4885PIK3CD 801/4885PIK3CB 727/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | PIK3CA 60/4885PIK3CD 195/4885PIK3CB 247/4885 |
| US-20260007665-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | KRAS, NRAS, HRAS | PIK3CA 229/4885PIK3CD 382/4885PIK3CB 460/4885 |
| US-12583854-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, APC | PIK3CA 1038/4885PIK3CD 1223/4885PIK3CB 1770/4885 |
| US-12540129-B2 | KIF18A inhibitors | KIF18A, KIFC1, KIF2C | PIK3CA 309/4885PIK3CD 304/4885PIK3CB 191/4885 |
| US-20260098029-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIFC1 | PIK3CA 830/4885PIK3CD 712/4885PIK3CB 603/4885 |
| US-11306087-B2 | Inhibitors of KRAS G12C and methods of using the same | KRAS, NRAS, HRAS | PIK3CA 98/4885PIK3CD 431/4885PIK3CB 464/4885 |
| US-12582657-B2 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | KRAS, NRAS, BRAF | PIK3CA 19/4885PIK3CD 82/4885PIK3CB 244/4885 |
| US-11236069-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | PIK3CA 244/4885PIK3CD 253/4885PIK3CB 182/4885 |
| US-20220056015-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | PIK3CA 248/4885PIK3CD 265/4885PIK3CB 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.